2026BPD Chengdu Conference Final Schedule! Upgrade to a full pass for just 0 yuan | See you 11-6
2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted by Eumedic, co-organized by Kelun-Biotech, with Jingze Bio, Haibowei Pharma, Zhishan Weixin, and Wiszhen Bio serving as Innovation Partners.
Gather on-site2000+Professional Buyers,70+Keynote Speakers, Built for ImpactTechnical Forum, Full-Chain Exhibition, BPD Match, Executive RoundtableThe multi-faceted sessions, centered on technical reports and case studies, facilitate CMC professional exchanges by building an efficient platform focused on deep expertise and practical problem-solving.Get a quick look at the latest conference schedule. Register now for a free meal voucher, or contact Xiao Yi to upgrade your pass for 0 yuan!
Conference Schedule Updated
Schedule updated through 10/16
11 5, Venue 1
Opening Forum: Industrial Ecosystem & Full Process Chain
09:00-09:05 Opening Remarks
09:05-09:50 Interview: Source Innovation and Global Competition: New Paradigms and Cycles for Chinese Innovative Drug Companies
Moderator: Li Kechun, Partner at Yuan Sheng Capital
Guest: Xiang Yu, CEO of Boryao Biologics
Zheng Yubo, CFO of Chengdu Tianfu International Bio-city Development Group and General Manager of Guosheng Capital
Chen Dexiang, Chairman & General Manager, Makang Bio
09:50-10:30 Interview: Differentiated Strategies of Frontier Molecules
Guest: Chen Su, General Manager of Chengdu Weijin Biology
Li Weimin, Abio Bio, President of Preclinical R&D
Li Jianguang, Haichang Bio, CSO
Li Shude, former Chief Manufacturing Officer at China Resources BiologyNEW
Innovative Development of Upstream Biopharmaceutical Processes
11:00-11:20 Report: Design of Multifunctional Fusion Proteins and CMC Development Strategies
Guest: Wang Zhenyu, Senior Director, GEMCare
11:20-11:40 Report: Cutting-Edge Strategies for Developing High-Yield Cell Lines for Complex Molecules
Guest: Zhang Yu, Vice Director of Process Development, Sanjiu Guojian
11:40-12:00 Report: Process Feasibility for Ongoing Projects
Speaker: Zhao Yanyan, Senior Director of Process Development Center, Bo-Ant Biopharma
12:00-12:20 Report: ADC Process Development Direction
Guest: Dong Fusheng, Operations Director, Chongqing Haoyuan
12:20-12:30 Q&A
12:30-13:30 Lunch Chat
Innovation Development of Downstream Biopharmaceutical Processes
13:30-13:50 Report: Design and Process Development of Fusion Proteins
Guest: Huang Haiqiu, Vice Dean and Director of R&D, Jeku Biotech
13:50-14:10 Report: Enhancing Downstream Processing Technologies: Application of Membrane Chromatography in Antibody Purification
Guest: Zhao Puya, Head of Downstream Technology at Cayman Biopharm
14:10-14:30 Report: Challenges and Strategies in Complex Antibody Purification Processes
Guest: Zhu Ying, Head of Downstream Process, Zhenge Biotechnology
14:30-14:50 Q&A
Masterclass
14:50-15:30 Report: Biotherapeutic Contamination Control Strategy and Inspection Deficiencies
Guest: Hongyu Tan, a senior domestic pharmaceutical GMP expert and former core inspector at CFDI.
15:30-16:00 Tea Break Networking
ADC Manufacturing Process and Quality Control
16:00-16:20 Report: Strategy and Practice for Comparability Studies of ADC DrugsNEW
Guest: Qu Yaocheng, Vice Director of Quality Control Department, Sinopharm Crosslink
16:20-16:40 Report: Key Points on ADC Special QC Strategy, Hardware Facilities, and Workshop Layout (Draft)
Guest: Professor Park, former head of the Drug GMP Inspection Team at the National Medical Products Administration
16:40-17:00 Report: Iterative CMC Strategy Upgrade Overcomes Scaling Challenges for Next-Generation Conjugate Drugs
Guest: Hongbin Song, Senior Director of ADC CMC at Innovent Biologics
17:00-17:20 Report: Quality Research and Control Strategy for XDC Drugs
Guest: Xu Ying,皓元医药 (Hao Yuan Pharmaceutical), Director / Head of ARD
Report: Analytical Characterization Challenges for Complex Molecules (ADCs, Bispecific Antibodies, and Fusion Proteins)
Guest: Mingze Sun, CMC Director at Tian Guangshi Biotech
17:40-17:50 Q&A
11 5 [Venue 2]
CGT R&D Innovation Forum
09:50-10:10 Report: Key Considerations in Developing CAR-T Therapies In Vivo
Guest: Hana He, Senior Director of R&D at Fosun Kary
10:10-10:30 Report: Development of In Vivo LNP Delivery Systems
Guest: Gu Yongjun, Wiszen Biotech, Partner & Head of CMC and Intellectual Property
High-level Strategy
11:00-11:50 Interview: How CGT Creates a True Closed Loop of "Innovation, Compliance, and Accessibility"NEW
Moderator: Chen Lijing, Vice President and COO, Jinweike Bio
Guests: Tan Binghe, CTO of Bionuo Biopharma; Wang Yue, Executive Director and Chair of the Cell and Gene Product Regulatory Research Committee at the China Association for Pharmaceutical Administration; He Ruina, Senior R&D Director at Fosun Karyopharm.
11:50-12:30 Interview: How Nucleic Acid Drugs Bridge the Gap from Technology Platform to Pipeline
Moderator: Zhang Zheng, Head of Southwest Investment at Huage Capital
Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center
Gu Yongjun, Vazson Bio, Partner & Head of CMC and Intellectual Property Li Jiangguang, Haichang Bio, CSO
Innovative R&D and Scalable Production of Peptide Drugs
13:30-13:50 Report: CR059: Long-Acting Efficacy of Circular RNA Encoding a GLP-1 Analog
Guest: Peiya, Chief Director of Early Drug R&D at PegBio
13:50-14:10 Report: Discovery and Engineering of Metabolic Polypeptide Drugs
Guest: Nie Yunyu, Chief Scientist of Metabolic Peptide Engineering at Innovent Biologics
14:10-14:30 Report: Natural Peptide Library & AI Discovery Platform
Guest: Liu Lulu, BD Director, PedBio
14:30-14:50 Report: Formulation Development Direction (Provisional)
Speaker: Yang Fengyun, Director of Formulation Development, Gansun Pharmaceutical
14:50-15:10 Report: Peptide Drug Process Scale-Up and Large-Scale Production (Provisional)
Guest: Li Changfeng, Senior R&D Supervisor, Chemical Macromolecules Division, AuroChem (Catalyst)
15:10-15:30 Report: Risk-Based Impurity Studies for GLP-1 Recombinant DrugsNEW
Guest: Liu Hedong, Senior Manager of Microbial Process Development Platform & Hengqin Early Development Platform, Federal Biotech
15:30-16:00 Tea Break Networking
Innovative Development of Nucleic Acid Drugs and Extracellular Delivery Innovations
16:00-16:20 Report: From COVID-19 to Oncology — The Paradigm Shift in mRNA Therapy Commercialization
Guest: Li Weimin, President of Preclinical R&D at Abogen
16:20-16:40 Report: Dual-Target siRNA Drug
Guest: Yu Shuowen, Director of Nucleic Acid Medicinal Chemistry at Xianyan Bio
16:40-17:00 Report: From Identification to Delivery: Applications of Nucleic Acid Aptamers in Extrahepatic Targeted Delivery
Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center
17:00-17:20 Report: Novel Lipid Nanoparticle-Based Nucleic Acid Delivery System
Guest: Li Jianguang, Haichang Biopharma, CSO
11/5 [Venue 3]
11:00-13:00 Exclusive Lunch
14:00-15:30 Executive Closed-Door Meeting
High-Level Closed-Door Meeting: Western Pharmaceutical Companies' Strategy and Choices in the AI Era
30 C-level executives and technical leaders from pharma/biotech
14:00-14:20 Report: How R&D Systems Are Reimagined with AI — From Target to Candidate Molecule
14:20-14:40 Report: How R&D Teams Are Using AI to Rebuild Knowledge Management and Cross-Functional Collaboration
14:40-15:30 Discussion: From "Heard It" to "Thought Through It" — Three Key Questions for AI Decision-Making
Outline
1: Should you join now? — Strategic timing assessment
2: How to Spend Your First Budget — Investment and Path
3 How to Select the Right Partner: Vetting and Risk Control
AI In Drug Discovery
16:00-16:20 Report: AI Antibody De Novo Design and Agent Platform Empowering Antibody Drug Discovery
Guest: Wang Tianyuan, CEO of Combiotech
16:20-16:40 Report: Data Security for AI in Biopharmaceutical Companies: From Knowledge Retrieval to Agent Execution
Guest: Liu Qihé, TransBio, Head of AI Development
16:40-17:00 Report: Intelligent Automation Discovery Platform - Differentiated Discovery Strategies for Next-Generation ADC/XDC Drugs
Guest: Zhang Hongwei, Chief Information Officer and Managing Director of Beijing at Kede Pharma
17:00-17:10 Q&A
11 6 [Venue 1]
Regulations and On-site Verification
09:00-09:20 Report: Scientific Regulation, Innovative Drug Development for Benefit
Guest: Ran Zhang, Beihe Kangcheng, Chief Regulatory Advisor
09:20-09:40 Report: Regulatory Strategy for Dual IND Filing of Innovative Drugs in China and the USNEW
Guest: Lei Juan, Registration Director, Hansi Aite
09:40-10:00 Report: Promoting Research through Regulation — Key Points for Clinical Evaluation in New Drug Marketing Applications
Guest: Chen Yangqi, Chengdu Xuyuan Biology, COO
10:00-10:20 Report: Differences in Pharmaceutical Registration Submissions and CMC Regulation Between Domestic and International Markets
10:20-10:30 Q&A
10:30-11:00 Tea Break Networking
Commercialization of Biologics Manufacturing
11:00-11:20 Report: Entrusted Production Management Under the MAH SystemNEW
Guest: He Yanchao, Simcere Pharmaceutical Group, Head of Quality/Qualified Person
11:20-11:40 Report: Key Success Factors for Technology Transfer (Provisional)
Guest: Li Hongcheng, Director of Upstream Process Development, Sinopharm Jinke
11:40-12:00 Report: Key Elements and Practices for Pre-Market Commercial Manufacturing in Biopharmaceuticals
Guest: Yang Shiming, Director of Production, Chubb Bio
12:00-12:20 Report: Mass Production Reshapes the Global Bio-Manufacturing Landscape
Guest: Liu Aibing, CMC Director at Bibo Biological
12:20-12:30 Q&A
12:30-13:30 Lunch Chat
AI for Pharma: Masterclass
13:30-14:30 Report: Biopharmaceuticals – Planning, Building, and Excelling in Smart Digital Factories
Guest: Li Shude, former Chief Manufacturing Officer of China Resources Biology
AI-Enabled CMC Development for Biopharmaceuticals
14:30-14:50 Report: Research on AI Digitalization, Compliance, and Enterprise Benefits
Guest: Ma Jun, former Vice President of Junshi Biosciences
14:50-15:10 Report: AI-Empowered CMC and Compliance Considerations for Biologics
Guest: Dongqiang Lin, Zhejiang University, Professor
AI-Driven Commercial Biopharmaceutical Manufacturing
15:10-15:30 Report: Digital Transformation of Biopharmaceutical Manufacturing:
Henlius: Practices and Insights
Guest: Wei Gong, General Manager of ADC Development and Clinical Manufacturing at MacroGenics
15:30-15:50 Report: The Path and Practice of Digital Intelligence Advancement for Pharmaceutical Enterprises
Guest: Zhu Xiaofeng, Deputy General Manager of the Intelligent Data Department, China Resources Double Crane
15:50-16:30 Interview: Digital Intelligence Breakthrough and Efficiency Revolution in Commercial Biopharmaceutical Manufacturing
Guest: Ma Jun, former Vice President of Junshi Biosciences
Dongqiang Lin, Zhejiang University, Professor
Sheng Zhe, Director of Intelligent Data Department, CR SanheNEW
Li Shude, former Chief Manufacturing Officer at China Resources Biology
Shiming Yang, Bu Chang Bio, Production Director
Tan Hongyu, a senior domestic GMP expert in the pharmaceutical industry and former core inspector at CFDI.
11 6 [Venue 2]
Innovative R&D of Complex Molecules
09:00-09:20 Report: Development of Bispecific ADCs and Dual-Payload ADCs
09:20-09:40 Report: Innovative ADC Development (Tentative)
Guest: Zhenwei Miao, Chairman and CEO of Ake Rui Si & Ying Bai Rui
09:40-10:00 Report: Pending
Guest: Song Xiangrong, Founder of Vistron Bio
10:00-10:20 Report: Progress in KRAS Inhibitor Development
Guest: Li Yingfu, Founder & Chairman of Haibowei Pharmaceuticals
10:20-10:30 Q&A
10:30-11:00 Tea Break Networking
Innovative R&D and CMC Development Strategies for Radiopharmaceuticals
11:00-11:40 Interview: Industrial Breakthrough and Commercial Path Selection for the Full Nuclear Medicine Chain
Host: Niun Xingle, Huajin Capital
Guest: Chen Dianjun, President and CSO of Chengdu Xingrui Jingxuan Biotechnology
Bai Ge, Guotong New Drugs, COO
Wang Zheng, CEO of Sinotrac Nuclear Medicine
Xiahai Hong, Chief Scientist at Guodian Tuhe Chuangxin (Chongqing) Technology Co., Ltd.
11:40-12:00 Report: The Critical Role of Novel Metal Chelators in Radiopharmaceutical Development
Guest: Wang Zheng, CEO of Sinotrac Nuclear Medicine
12:00-12:20 Report: Three Major Challenges in Producing Alpha Emitters via Medium- and High-Energy Proton AcceleratorsNEW
Guest: Xia Haihong, Chief Scientist, SPIC Nuclear Isotope Innovation (Chongqing) Technology Co., Ltd.
12:20-12:30 Q&A
12:30-13:30 Lunch Chat
Innovative CGT Therapy Development
13:30-13:50 Report: Development and Progress of rAAV Gene Therapy for Aging-Related Diseases
Guest: Dong Biao, Founder of Zhishan Weixin
13:50-14:10 Report: Research and Application of Cytoimmune Cell Therapy in Preventing Tumor Recurrence
Guest: Liu Dun, Vice President of Saide Biotech
14:10-14:30 Report: Progress in MSC Therapy for Liver Disease (Tentative)
Guest: Tan Yi, Vice President and Director of R&D at Qilu Cell Therapy
14:30-14:50 Report: Advances in Drug Research Derived from Pluripotent Stem Cells
Guest: Yan Xiang, Director of R&D, CloudTest Medicine
Innovative CGT Therapy Process Development and Scalable Manufacturing
14:50-15:10 Report: Key Points for CGT Production Verification
Guest: Teacher Tu, Regulatory Expert
15:10-15:30 Report: The World's First Gene Therapy Drug Development Platform Based on a Dual-Plasmid Process
Guest: Chen Lijing, COO/VP of Jinweike Bio
15:30-15:50 Report: Clinical Practice for Quality Control Standards of Small Extracellular Vesicles
Guest: Yang Shuangshuang, Research and Development Manager, Qilu Cell Therapy
15:50-16:10 Report: Automated Closed-System Stem Cell Production
Guest: Wu Shouliang, Deputy Director of Production Technology at Sino-Union
11/6 [Venue 3]
AI In Drug Discovery
09:10-09:30 Report: AI-Driven Nucleic Acid Drug Development and Clinical Translation
Guest: Liang Zhang, Researcher at the Hangzhou Institute of Medicine, Chinese Academy of Sciences
09:30-09:50 Report: Discovery of Novel Tumor Immunotherapy Targets and New Drug Development Based on Artificial Intelligence
Guest: Shijun Shi, Professor at Chengdu University of Traditional Chinese Medicine
09:50-10:30 Interview: The "Last Mile" of AI Drug Discovery – Bridging the Gap from Molecular Generation to Clinical Success
Host: Wang Tianyuan, CEO of Combi-Bio
Guest: Shi Sanjun, Professor, Chengdu University of Traditional Chinese Medicine
Liu Qihé, TransInfo Biotech, Head of AI Development
Zhang Liang, Researcher, Hangzhou Institute of Medicine, Chinese Academy of Sciences
Complex Molecular Process Development
11:00-11:20 Report: Formulation Stability and Process Scale-up Challenges
11:20-11:40 Report: Quality System Resilience Behind FDA's Three Inspections
11:40-12:30 Interview: The Evolution of CMC Across Stages – From Technical Challenges to Commercial SuccessNEW
Moderator: Tang Defang, Vice President of Jingze Bio
Guest: Ran Gugu, Salubris (Chengdu), Director of Project Management
Song Qingguo, Founder of Guanlan (Hong Kong) Medicine
Small-Molecule Innovative Development and Manufacturing
13:30-13:50 Report: Discovery of Novel Tumor Immunotherapy Targets and New Drug Development Based on Artificial Intelligence
Guest: Shijun Shi, Professor at Chengdu University of Traditional Chinese MedicineNEW
13:50-14:10 Report: Strategies for Enhancing Solubility of Poorly Soluble Small Molecule Drugs
14:10-14:30 Report: Formulation Strategy for Modified New Drugs (Category 2)
14:30-15:30 Discussion: Ecological Gaps and Synergistic Pathways in Small-Molecule Drug Innovation

